Please login to the form below
Zontivity
This page shows the latest Zontivity news and features for those working in and with pharma, biotech and healthcare.
FDA reviewer backs approval of TMC's cangrelor
Additional competition in the category will also come from Merck &Co's first-in-class protease-activated receptor-1 (PAR-1) antagonist Zontivity (vorapaxar) - which was cleared for marketing in the
Latest news
-
R&D productivity takes off
Other first-in-class agents include: Merck &Co's PAR-1 antagonist Zontivity (vorapaxar), a novel antiplatelet agent; AstraZeneca's PARP inhibitor Lynparza (olaparib) for cancer; Otsuka's Deltyba (delamanid), a
-
Orphan drugs in latest CHMP recommendations
s Zontivity (vorapaxar), which was recommended for the reduction of atherothrombotic events.
-
Merck's first-in-class Zontivity cleared in US
After a long haul, Merck &Co's Zontivity has become the first drug in the new protease-activated receptor-1 (PAR-1) antagonist class to be approved for marketing in the ... Merck plans to launch Zontivity in the US in the coming weeks, while the PAR-1
-
FDA panel backs Merck's vorapaxar
Vorapaxar - which Merck plans to sell under the brand name Zontivity - is an orally-active protease-activated receptor 1 (PAR-1) inhibitor that targets thrombin-induced platelet activation. ... If the FDA follows the panel's advice - which it generally
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Deal Watch September 2016
Merck &Co has sold the US and Canadian rights for its Zontivity, or vorapaxar, to Aralez Pharmaceuticals in an asset purchase agreement worth $25m. ... Zontivity is a protease-activated receptor-1 antagonist indicated for use in combination with daily
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How will the events and exhibitions industry change post-Coronavirus?
- Lilly’s Verzenio scores a win in early-stage breast cancer
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Switzerland: a life sciences hub
- FDA approves Roche’s Actemra COVID-19 trial
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- The concordance conundrum: creating space for open dialogue
- Webinar: Maintaining market access through a pandemic, 6 months on
- Researchers call on Pfizer to delay COVID-19 vaccine application
- Inovio hit with FDA hold on COVID-19 vaccine trial
- Switzerland: a life sciences hub
- Responding to dynamic shifts in value communications
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- The concordance conundrum: creating space for open dialogue
- Growing numbers of patients want a partnership model with their HCP, whereby both parties are equally involved in the decision-making process. This model has been linked with an increase in...
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Quick links
Infographics
